Betaine treatment attenuates chronic ethanol-induced hepatic steatosis and alterations to the mitochondrial respiratory chain proteome [0.03%]
甜菜碱治疗缓解慢性乙醇诱导的肝脂肪变性和线粒体呼吸链蛋白组学改变
Kusum K Kharbanda,Sandra L Todero,Adrienne L King et al.
Kusum K Kharbanda et al.
Introduction. Mitochondrial damage and disruption in oxidative phosphorylation contributes to the pathogenesis of alcoholic liver injury. Herein, we tested the hypothesis that the hepatoprotective actions of betaine against alcoholic liver ...
The molecular pathogenesis and clinical implications of hepatocellular carcinoma [0.03%]
肝细胞癌的分子发病学和临床意义
Makoto Meguro,Toru Mizuguchi,Masaki Kawamoto et al.
Makoto Meguro et al.
The prognosis of hepatocellular carcinoma (HCC) is affected by tumoral factors and liver functions; therefore it is often difficult to select the appropriate therapeutic methods for HCC. Recently, two global phase III trials showed that sor...
Deepak Amarapurkar,Rajiv Jalan,Richard Guan et al.
Deepak Amarapurkar et al.
Role of tumor associated fibroblasts in human liver regeneration, cirrhosis, and cancer [0.03%]
肿瘤相关成纤维细胞在人肝脏再生、肝硬化和癌症中的作用
Daniela Cesselli,Antonio Paolo Beltrami,Alessandra Poz et al.
Daniela Cesselli et al.
Tumor associated fibroblasts (TAFs) are considered a microenvironmental element critical for tumor growth and progression. Experimental studies suggest that their origin could be from mesenchymal stem cells (MSCs) derived from the bone marr...
Dose-Dependent Change in Elimination Kinetics of Ethanol due to Shift of Dominant Metabolizing Enzyme from ADH 1 (Class I) to ADH 3 (Class III) in Mouse [0.03%]
小鼠乙醇消除动力学的剂量依赖性变化及其代谢酶由ADH1（Ⅰ类）向ADH3（Ⅲ类）转换的关系研究
Takeshi Haseba,Kouji Kameyama,Keiko Mashimo et al.
Takeshi Haseba et al.
ADH 1 and ADH 3 are major two ADH isozymes in the liver, which participate in systemic alcohol metabolism, mainly distributing in parenchymal and in sinusoidal endothelial cells of the liver, respectively. We investigated how these two ADHs...
Management of coagulopathy in patients with decompensated liver cirrhosis [0.03%]
失代偿期肝硬化患者的凝血功能障碍的治疗
Pooja D Amarapurkar,Deepak N Amarapurkar
Pooja D Amarapurkar
Patients with decompensated liver cirrhosis have significantly impaired synthetic function. Many proteins involved in the coagulation process are synthesized in the liver. Routinely performed tests of the coagulation are abnormal in patient...
Oxaliplatin but not irinotecan impairs posthepatectomy liver regeneration in a murine model [0.03%]
在小鼠模型中，奥沙利铂而非伊立替康会抑制肝切除后的肝脏再生
Perry A Soriano,Nian Liu,Erick Castillo et al.
Perry A Soriano et al.
Introduction. We examined the murine hepatectomy model of liver regeneration (LR) in the setting of neoadjuvant chemotherapy. Methods. C57BL/6 mice were randomized to receive neoadjuvant intraperitoneal (IP) injections of a control, oxalipl...
Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment [0.03%]
选择性内放射治疗胃肠神经内分泌肿瘤肝转移：一种新的有效治疗手段
Harshal Rajekar,Kashan Bogammana,Richard S Stubbs
Harshal Rajekar
Background. Nonresectable neuroendocrine tumour (NET) liver metastases respond poorly to most widely available and used therapies. Selective Internal Radiation Therapy (SIRT) is becoming recognized as a new modality for selectively treating...
The impact of antiviral therapy and the influence of metabolic cofactors on the outcome of chronic HCV infection [0.03%]
抗病毒治疗及代谢共因子对慢性丙型肝炎病毒感染的影响
Marcello Persico,Savino Bruno,Andrea Costantino et al.
Marcello Persico et al.
NATURAL HISTORY OF HCV RELATED CHRONIC HEPATITIS IS INFLUENCED AND MODIFIED BY MANY FACTORS: virus features, coinfections and host characteristics. In particular, a peculiar genetic background of the host by conditioning the occurrence of i...
Liver resection after downstaging hepatocellular carcinoma with sorafenib [0.03%]
索拉非尼桥接治疗降期后的肝细胞癌手术切除
L Barbier,F Muscari,S Le Guellec et al.
L Barbier et al.
Background. Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma in Child A patients. Aims. To address the question of sorafenib as neoadjuvant treatment. Methods. We describe the cases...